Spleen tyrosine kinase family (Syk family) (Syk family)

The Spleen tyrosine kinase (Syk) family consists of non-receptor tyrosine kinases, primarily Syk and ZAP-70, which are essential mediators of immunoreceptor signaling (Source: UniProt P43405, P43403). Syk is broadly expressed in hematopoietic cells such as B cells, mast cells, and macrophages, where it couples the B-cell receptor (BCR) and Fc receptors to downstream pathways like PLC-gamma and PI3K (Source: PubMed PMID: 25639649). ZAP-70 is predominantly expressed in T cells and natural killer cells, playing a critical role in T-cell receptor (TCR) signaling and T-cell development (Source: StatPearls NBK559033). Dysregulation or overactivation of these kinases is implicated in various autoimmune disorders, such as rheumatoid arthritis and immune thrombocytopenia (ITP), as well as B-cell malignancies like chronic lymphocytic leukemia (Source: PubMed PMID: 29100310). Therapeutic targeting of the Syk family, particularly with small-molecule inhibitors like fostamatinib, has proven effective in managing chronic ITP by reducing antibody-mediated platelet destruction (Source: FDA Tavalisse Label). Ongoing research explores the potential of Syk inhibitors in treating allergic asthma and various solid tumors where Syk signaling may contribute to disease progression (Source: PubMed PMID: 31434380). These inhibitors typically function by competing with ATP for the binding site in the kinase domain, thereby preventing the phosphorylation events necessary for signal propagation (Source: PubMed PMID: 29100310). Clinical challenges include managing off-target effects and systemic toxicities such as hypertension and gastrointestinal distress (Source: FDA Tavalisse Label).

Other names

Syk/Zap-70 familySpleen tyrosine kinaseZeta-chain-associated protein kinase 70SYKZAP70

Small molecule inhibition of the ATP-binding site within the kinase domain, preventing autophosphorylation and downstream signaling (Source: PubMed PMID: 29100310).